#Post ADS3

advertisement

Cefixime Oral: Uses, Side Effects, Interactions , Cefixime (Oral Route) Side Effects



Ingredient: Cefixime USP 200 mg Capsule, 400 mg DS capsule, 100mg / 5ml Suspension and 200mg / 5ml Fort Suspension.

Instructions: Upper and lower respiratory infections, urinary tract infections, gonococcal urethritis, acute otitis media.

Terms and Conditions: Cefixime capsule / tablet: 200m GRA - 400m G., according to the intensity of the disease up to 7-14 days in single or split levels.
Cefixime Suspension Powder: Children's Dimension: 8mg daily Seven or 14 days of physical weight per kg or 7-14 days or so
1/2 to 1 year: 75 mg
1-4 years until 100mg
Up to 5-10 years: 200mg
Up to 11-12 years: 300mg
Over 12 years: full adult dimensions

Side effects: Generally Cefixime is helpful. The side effects that are seen in the clinical trial are mostly mild and temporary.
Disease response (GIT): Diarrhea (if it is fatal, should stop using the Cefixime, change in the color of the toilet, vomiting, abdominal pain, indigestion.
Central nervous system (CNS) response: Headaches can be swollen.
Other responses: Hypersensitivity response that is healing when the treatment is stopped. Hematologic reaction that is very rare and increases the amounts of serum amyelage.

Incompetence: Those who have hyperactivity in Cephalosporin medicines.

Caution: Those who have problems with digestion, especially if there are colitis, Cefixime should be used with caution. Only patients who have serious problems with adolescence may need to change the level.

During pregnancy and during breastfeeding: It is better to avoid taking Cefixime during pregnancy and breastfeeding because there is no clinical information in this case.

In case of the elderly: No special caution is required.

In children's case: For children under 12 or less than 50 kg daily, 8mg daily Sevya as per kJee

āĻ‰āĻĒাāĻĻাāĻ¨ : āĻ¸েāĻĢিāĻ•্āĻ¸িāĻŽ (āĻ¸েāĻĢিāĻ•্āĻ¸িāĻŽ āĻŸ্āĻ°াāĻ‡āĻšাāĻ‡āĻĄ্āĻ°েāĻŸ āĻ‡āĻ‰ āĻāĻ¸āĻĒি āĻšিāĻ¸েāĻŦে)। ā§¨ā§Ļā§Ļ āĻŽি.āĻ—্āĻ°া. āĻ•্āĻ¯াāĻĒāĻ¸ুāĻ˛, ā§Ēā§Ļā§Ļ āĻŽি.āĻ—্āĻ°া. āĻĄিāĻāĻ¸ āĻ•্āĻ¯াāĻĒāĻ¸ুāĻ˛, ā§¨ā§Ļā§Ļ āĻŽি.āĻ—্āĻ°া.  ā§§ā§Ļā§Ļ āĻŽি.āĻ—্āĻ°া./ā§Ģ āĻŽি.āĻ˛ি.āĻ¸াāĻ¸āĻĒেāĻ¨āĻļāĻ¨ āĻāĻŦং ā§¨ā§Ļā§Ļ āĻŽি.āĻ—্āĻ°া./ā§Ģ āĻŽি.āĻ˛ি. āĻĢোāĻ°্āĻŸ āĻ¸াāĻ¸āĻĒেāĻ¨āĻļāĻ¨।

āĻ¨িāĻ°্āĻĻেāĻļāĻ¨া : āĻ‰āĻ°্āĻ§্āĻŦ āĻ“ āĻ¨িāĻŽ্āĻ¨ āĻļ্āĻŦাāĻ¸āĻ¤āĻ¨্āĻ¤্āĻ°েāĻ° āĻ¸ংāĻ•্āĻ°āĻŽāĻŖ, āĻŽূāĻ¤্āĻ° āĻ¨াāĻ˛ীāĻ° āĻ¸ংāĻ•্āĻ°āĻŽāĻŖ, āĻ—āĻ¨োāĻ•āĻ•্āĻ•াāĻ˛ āĻ‡āĻ‰āĻ°েāĻĨ্āĻ°াāĻ‡āĻŸিāĻ¸, āĻāĻ•িāĻ‰āĻŸ āĻ“āĻŸাāĻ‡āĻŸিāĻ¸ āĻŽিāĻĄিāĻ¯়া।

āĻŦ্āĻ¯āĻŦāĻšাāĻ°āĻŦিāĻ§ি āĻ“ āĻŽাāĻ¤্āĻ°া :āĻ¸েāĻĢিāĻ•্āĻ¸িāĻŽ āĻ•্āĻ¯াāĻĒāĻ¸ুāĻ˛/āĻŸ্āĻ¯াāĻŦāĻ˛েāĻŸঃ ā§¨ā§Ļā§Ļ āĻŽি. āĻ—্āĻ°া. - ā§Ēā§Ļā§Ļ āĻŽি. āĻ—্āĻ°া., āĻāĻ•āĻ• āĻŦা āĻŦিāĻ­āĻ•্āĻ¤ āĻŽাāĻ¤্āĻ°াāĻ¯় ā§­-ā§§ā§Ē āĻĻিāĻ¨ āĻĒāĻ°্āĻ¯āĻ¨্āĻ¤ āĻ°োāĻ—েāĻ° āĻ¤ীāĻŦ্āĻ°āĻ¤া āĻ…āĻ¨ুāĻ¯াāĻ¯়ী āĻ¸েāĻŦ্āĻ¯।
āĻ¸েāĻĢিāĻ•্āĻ¸িāĻŽ āĻ¸াāĻ¸āĻĒেāĻ¨āĻļāĻ¨ āĻ¤ৈāĻ°ীāĻ° āĻĒাāĻ‰āĻĄাāĻ°ঃ āĻļিāĻļুāĻĻেāĻ° āĻŽাāĻ¤্āĻ°াঃ āĻĻৈāĻ¨িāĻ• ā§Ž āĻŽি.āĻ—্āĻ°া. āĻĒ্āĻ°āĻ¤ি āĻ•েāĻœি āĻĻৈāĻšিāĻ• āĻ“āĻœāĻ¨ āĻšিāĻ¸াāĻŦে āĻāĻ•āĻ• āĻŦা āĻĻুāĻŸি āĻŦিāĻ­āĻ•্āĻ¤ āĻŽাāĻ¤্āĻ°াāĻ¯় ā§­-ā§§ā§Ē āĻĻিāĻ¨ āĻĒāĻ°্āĻ¯āĻ¨্āĻ¤ āĻ¸েāĻŦ্āĻ¯ āĻ…āĻĨāĻŦা
ā§§/ā§¨-ā§§ āĻŦāĻ›āĻ° āĻĒāĻ°্āĻ¯āĻ¨্āĻ¤ঃ ā§­ā§Ģ āĻŽি.āĻ—্āĻ°া.
ā§§-ā§Ē āĻŦāĻ›āĻ° āĻĒāĻ°্āĻ¯āĻ¨্āĻ¤ঃ ā§§ā§Ļā§Ļ āĻŽি.āĻ—্āĻ°া.
ā§Ģ-ā§§ā§Ļ āĻŦāĻ›āĻ° āĻĒāĻ°্āĻ¯āĻ¨্āĻ¤ঃ ā§¨ā§Ļā§Ļ āĻŽি.āĻ—্āĻ°া.
ā§§ā§§-ā§§ā§¨ āĻŦāĻ›āĻ° āĻĒāĻ°্āĻ¯āĻ¨্āĻ¤ঃ ā§Šā§Ļā§Ļ āĻŽি.āĻ—্āĻ°া.
ā§§ā§¨ āĻŦāĻ›āĻ°েāĻ° āĻ‰āĻ°্āĻĻ্āĻ§েঃ āĻĒূāĻ°্āĻŖ āĻŦāĻ¯়āĻ¸্āĻ• āĻŽাāĻ¤্āĻ°া

āĻĒাāĻ°্āĻļ্āĻŦ āĻĒ্āĻ°āĻ¤িāĻ•্āĻ°িāĻ¯়া : āĻ¸াāĻ§াāĻ°āĻŖāĻ¤ঃ āĻ¸েāĻĢিāĻ•্āĻ¸িāĻŽ āĻ¸ুāĻ¸āĻšāĻ¨ীāĻ¯়। āĻ¯ে āĻ¸āĻŦ āĻĒাāĻ°্āĻļ্āĻŦ āĻĒ্āĻ°āĻ¤িāĻ•্āĻ°িāĻ¯়া āĻ•্āĻ˛িāĻ¨িāĻ•্āĻ¯াāĻ˛ āĻŸ্āĻ°াāĻ¯়াāĻ˛ে āĻĻেāĻ–া āĻ—েāĻ›ে āĻ¤াāĻ° āĻ…āĻ§িāĻ•াংāĻļāĻ‡ āĻŽৃāĻĻু āĻĒ্āĻ°āĻ•ৃāĻ¤িāĻ° āĻāĻŦং āĻ•্āĻˇāĻŖāĻ¸্āĻĨাāĻ¯়ী।
āĻĒāĻ°িāĻĒাāĻ•āĻ¤āĻ¨্āĻ¤্āĻ°ে (GIT) āĻĒ্āĻ°āĻ¤িāĻ•্āĻ°িāĻ¯়াঃ āĻĄাāĻ¯়āĻ°িāĻ¯়া (āĻ¯āĻĻি āĻŽাāĻ°াāĻ¤্āĻŽāĻ• āĻ†āĻ•াāĻ° āĻ§াāĻ°āĻŖ āĻ•āĻ°ে āĻ¤āĻŦে āĻ¸েāĻĢিāĻ•্āĻ¸িāĻŽ āĻ¸েāĻŦāĻ¨ āĻŦāĻ¨্āĻ§ āĻ•āĻ°া āĻ‰āĻšিāĻ¤), āĻĒাāĻ¯়āĻ–াāĻ¨াāĻ° āĻ°ং āĻĒāĻ°িāĻŦāĻ°্āĻ¤āĻ¨, āĻŦāĻŽিāĻŦāĻŽি āĻ­াāĻŦ, āĻĒেāĻŸে āĻŦ্āĻ¯āĻĨা, āĻ…āĻœীāĻ°্āĻŖāĻ¤া।
āĻ•েāĻ¨্āĻĻ্āĻ°ীāĻ¯় āĻ¸্āĻ¨াāĻ¯়ুāĻ¤āĻ¨্āĻ¤্āĻ°ে (CNS) āĻĒ্āĻ°āĻ¤িāĻ•্āĻ°িāĻ¯়াঃ āĻŽাāĻĨা āĻŦ্āĻ¯āĻĨা, āĻিāĻŽুāĻ¨ী āĻšāĻ¤ে āĻĒাāĻ°ে।
āĻ…āĻ¨্āĻ¯াāĻ¨্āĻ¯ āĻĒ্āĻ°āĻ¤িāĻ•্āĻ°িāĻ¯়াঃ āĻ…āĻ¤ি āĻ¸ংāĻŦেāĻĻāĻ¨āĻļীāĻ˛ (Hypersensitivity) āĻĒ্āĻ°āĻ¤িāĻ•্āĻ°িāĻ¯়া āĻ¯া āĻšিāĻ•িā§ŽāĻ¸া āĻŦāĻ¨্āĻ§ āĻ•āĻ°া āĻšāĻ˛ে āĻĒ্āĻ°āĻļāĻŽিāĻ¤ āĻšāĻ¯়। āĻšেāĻŽাāĻŸোāĻ˛āĻœিāĻ•্āĻ¯াāĻ˛ āĻĒ্āĻ°āĻ¤িāĻ•্āĻ°িāĻ¯়া āĻ¯া āĻ–ুāĻŦāĻ‡ āĻŦিāĻ°āĻ˛ āĻāĻŦং āĻ¸িāĻ°াāĻŽে āĻ…্āĻ¯াāĻŽাāĻ‡āĻ˛েāĻœ āĻāĻ° āĻĒāĻ°িāĻŽাāĻŖ āĻŦৃāĻĻ্āĻ§ি āĻĒাāĻ“āĻ¯়া।

āĻ…āĻ¨ুāĻĒāĻ¯োāĻ—িāĻ¤া : āĻ¯াāĻĻেāĻ° āĻ¸েāĻĢাāĻ˛োāĻ¸্āĻĒোāĻ°িāĻ¨ āĻœাāĻ¤ীāĻ¯় āĻ“āĻˇুāĻ§ে āĻ…āĻ¤িāĻ¸ংāĻŦেāĻĻāĻ¨āĻļীāĻ˛āĻ¤া āĻ†āĻ›ে।

āĻ¸াāĻŦāĻ§াāĻ¨āĻ¤া : āĻ¯াāĻĻেāĻ° āĻĒāĻ°িāĻĒাāĻ•āĻ¤āĻ¨্āĻ¤্āĻ°ে āĻ¸āĻŽāĻ¸্āĻ¯া āĻ†āĻ›ে āĻŦিāĻļেāĻˇ āĻ•āĻ°ে āĻ•োāĻ˛াāĻ‡āĻŸিāĻ¸ āĻĨাāĻ•āĻ˛ে āĻ¸েāĻĢিāĻ•্āĻ¸িāĻŽ āĻ¸াāĻŦāĻ§াāĻ¨āĻ¤াāĻ° āĻ¸াāĻĨে āĻŦ্āĻ¯āĻŦāĻšাāĻ° āĻ•āĻ°া āĻ‰āĻšিāĻ¤। āĻ¯ে āĻ¸āĻŦ āĻ°োāĻ—ীāĻ° āĻŦৃāĻ•্āĻ•েāĻ° āĻ•াāĻ°্āĻ¯āĻ•্āĻˇāĻŽāĻ¤াāĻ¯় āĻŽাāĻ°াāĻ¤্āĻŽāĻ• āĻ¸āĻŽāĻ¸্āĻ¯া āĻ†āĻ›ে āĻļুāĻ§ুāĻŽাāĻ¤্āĻ° āĻ¤াāĻĻেāĻ° āĻ•্āĻˇেāĻ¤্āĻ°েāĻ‡ āĻŽাāĻ¤্āĻ°া āĻĒāĻ°িāĻŦāĻ°্āĻ¤āĻ¨ āĻ•āĻ°াāĻ° āĻĒ্āĻ°āĻ¯়োāĻœāĻ¨ āĻšāĻ¤ে āĻĒাāĻ°ে।

āĻ—āĻ°্āĻ­াāĻŦāĻ¸্āĻĨাāĻ¯় āĻāĻŦং āĻ¸্āĻ¤āĻ¨্āĻ¯āĻĻাāĻ¨āĻ•াāĻ˛ে : āĻ—āĻ°্āĻ­āĻ•াāĻ˛ীāĻ¨ āĻ…āĻŦāĻ¸্āĻĨাāĻ¯় āĻāĻŦং āĻ¸্āĻ¤āĻ¨্āĻ¯āĻĻাāĻ¨āĻ•াāĻ˛ে āĻ¸েāĻĢিāĻ•্āĻ¸িāĻŽ āĻ—্āĻ°āĻšāĻŖে āĻŦিāĻ°āĻ¤ āĻĨাāĻ•াāĻ‡ āĻ­াāĻ˛ āĻ•েāĻ¨āĻ¨া āĻāĻ•্āĻˇেāĻ¤্āĻ°ে āĻ¤েāĻŽāĻ¨ āĻ•োāĻ¨ āĻ•্āĻ˛িāĻ¨িāĻ•্āĻ¯াāĻ˛ āĻ¤āĻĨ্āĻ¯ āĻ¨েāĻ‡।

āĻŦāĻ¯়āĻ¸্āĻ•āĻĻেāĻ° āĻ•্āĻˇেāĻ¤্āĻ°ে : āĻ•োāĻ¨ āĻŦিāĻļেāĻˇ āĻ¸াāĻŦāĻ§াāĻ¨āĻ¤াāĻ° āĻĒ্āĻ°āĻ¯়োāĻœāĻ¨ āĻ¨েāĻ‡।

āĻļিāĻļুāĻĻেāĻ° āĻ•্āĻˇেāĻ¤্āĻ°ে : ā§§ā§¨ āĻŦāĻ›āĻ°েāĻ° āĻ•āĻŽ āĻ…āĻĨāĻŦা ā§Ģā§Ļ āĻ•েāĻœিāĻ° āĻšেāĻ¯়ে āĻ•āĻŽ āĻ“āĻœāĻ¨েāĻ° āĻļিāĻļুāĻĻেāĻ° āĻ•্āĻˇেāĻ¤্āĻ°ে āĻĻৈāĻ¨িāĻ• ā§Ž āĻŽি.āĻ—্āĻ°া. āĻĒ্āĻ°āĻ¤ি āĻ•েāĻœিāĻ¤ে āĻšিāĻ¸াāĻŦে āĻ¸েāĻŦ্āĻ¯।

Post a Comment

0 Comments

advertisement

advertisement